LY-404,187 (or LY404187) is an ampakine (or "AMPA receptor potentiator") developed by Eli Lilly and Company. It is a member of the biarylpropylsulfonamide class of ampakines.
LY-404,187 has been demonstrated to enhance cognitive function in animal studies, and has also shown effects suggesting antidepressant action as well as having possible application in the treatment of schizophrenia, Parkinson's disease and ADHD. These effects appear to be mediated through multiple mechanisms of action secondary to AMPA receptor potentiation, with a prominent effect seen in research being increased levels of BDNF in the brain. It may therefore be continued on to human trials, although Eli Lilly has developed a whole family of biarylpropylsulfonamide derivatives and it is unclear at this stage which compound is most likely to be selected for further development.
^Jones N, O'Neill MJ, Tricklebank M, Libri V, Williams SC (2005). "Examining the Neural Targets of the AMPA Receptor Potentiator LY404187 in the Rat Brain Using Pharmacological Magnetic Resonance Imaging". Psychopharmacology180 (4): 743–751. doi:10.1007/s00213-005-2254-y. PMID15864556.
^O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES (2004). "AMPA Receptor Potentiators for the Treatment of CNS Disorders". Current Drug Targets. CNS and Neurological Disorders3 (3): 181–194. doi:10.2174/1568007043337508. PMID15180479.